eli lilly glp 1 oral FDA approves new weight-loss pill, Foundayo Medscape - Orforglipron, Eli Lilly's
Description
: In oncology, where trial binary outcomes loom large, platform leverage, disciplined valuation, and timing become critical drivers
Patent number: US10278961B2, CN108997332B, US20230138576A1
GLP-1 RAs approved by the US Food and Drug Administration (FDA) for T2DM and obesity (semaglutide, exenatide, liraglutide, tirzepatide, dulaglutide) were included in the analysis
We also pay close attention to electrolyte balance, as this can become disrupted with rapid weight loss
